Search
Inhibrx Biosciences Inc
INBXAdd to Watchlist
101.190USD
+0.860+0.86%
Market hours 09/24, 11:05（ET）
1.48BMarket Cap
LossP/E TTM
Inhibrx Biosciences Inc (INBX) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to Inhibrx Biosciences Inc in the past month.
Buy
1 Strong Buy
2 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
266.667USD+140.96%
INBX Analyst Recommendation Trends
In the current month, INBX has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. INBX average Analyst price target in the last month is 266.667.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
1
0
0
0
2
2
1
1
1
0
0
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
3
3
3
1
1
1
INBX Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, INBX EPS is projected to reach -2.523 in FY2026Q3, following reported EPS of -2.339 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-2.08
-1.79
-2.39
-2.52
-2.79
Actual
-2.11
-2.15
-2.34
--
--
Surprise
-1.76%
-20.07%
+2.13%
--
--
FAQs
What is Inhibrx Biosciences Inc's price target?
Analysts forecast that Inhibrx Biosciences Inc's price target is USD 266.67, with the highest forecast at USD 325.00 and the lowest forecast at USD 230.00.
How have Inhibrx Biosciences IncINBX's recent earnings per share performed?
The market expectation was USD -2.34, while Inhibrx Biosciences IncINBX's earnings per share (EPS) for the previous quarter was USD -2.15. EPS for the next quarter is expected at USD -2.52.
What is the analyst rating for Inhibrx Biosciences Inc?
Based on the ratings of Inhibrx Biosciences Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.